Heart valvular disease, aortic stenosis : Transcatheter aortic-valve replacement (TAVI) for high-risk patients
DISEASE INTERVENTION COMPARISON RESULTS
N Engl J Med. 2010 Oct 21;363(17):1597-607 Randomized Controlled Trial, Multicenter Study
IN heart valve disease, aortic stenosis, patients not candidates for surgical replacement The Use of
transcatheter aortic-valve replacement (TAVI)
As Treatment, Acute
Is better Than
standard therapy (including balloon aortic valvuloplasty)
To reduce all-cause death at 1 year: 31% TAVI VS 51% standard therapy. Also reduced hospitalizations and cardiac symptoms. Higher incidence of major strokes and vascular complications at 1 month, tought.
N Engl J Med. 2011 Jun 9;364(23):2187-98 Randomized Controlled Trial, Multicenter Study
IN heart valve disease, aortic stenosis, surgical high-risk patients The Use of
transcatheter aortic-valve replacement
As Treatment, Acute
Is equal Than
surgical aortic-valve replacement
To modify all-cause mortality at 1 year (24% transcatheter VS 27% surgical, p=0.44). At 30 days, major vascular events (inculding stroke) were more frequent with transcatheter (11%) than surgical (3%) method.